Select a Size
All Photos(2)
About This Item
Empirical Formula (Hill Notation):
C19H33NO2 · HCl
CAS Number:
Molecular Weight:
343.93
UNSPSC Code:
12352211
NACRES:
NA.77
Product Name
FTY720, ≥98% (HPLC)
SMILES string
Cl.NC(CO)(CO)CCc1ccc(cc1)CCCCCCCC
InChI
1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H
InChI key
SWZTYAVBMYWFGS-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
water: 10 mg/mL, clear
storage temp.
−20°C
Quality Level
Looking for similar products? Visit Product Comparison Guide
Related Categories
Application
FTY720 has been used as an immunomodulator and is used to investigate its effect on in vitro gastrulation model of P19C5 stem cells. It is also used to determine its efficacy in prolonging the survival corneal transplantation. FTY720 has been used to study its effect on the proliferation and differentiation of cultured embryonic hippocampal neural stem cells (NSCs) using the 5-bromo-2-deoxyuridine incorporation assay, the neurosphere formation assay and western blot analysis.
Biochem/physiol Actions
FTY720 is an immunomodulating drug and sphingosine 1-phosphate (S1P) receptor modulator. Phosphorylation of FTY270 by sphingosine kinase causes S1P1R internalization, which sequesters lymphocytes in lymph nodes, preventing them from taking part in an autoimmune response. Clinically, it has been approved for the treatment of multiple sclerosis (MS). It has also been shown to block and reverse paclitaxel-induced chemotherapy induced peripheral neuropathy (CIPN) through S1PR inhibition as well as inhibit the activity of histone deacetylases in the hippocampus of mouse brains, thereby modulating memory.
FTY720, an immunomodulating drug, acts as a sphingosine 1-phosphate (S1P) receptor modulator.
signalword
Warning
hcodes
pcodes
Hazard Classifications
STOT RE 2
target_organs
Immune system
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Goeril Karlsson et al.
Neurology, 82(8), 674-680 (2014-01-28)
To report outcomes of pregnancies that occurred during the fingolimod clinical development program. Pregnancy outcomes from phase II, phase III, and phase IV clinical studies (with optional extensions) were reported by clinical trial investigators. Fingolimod exposure in utero was defined
M Mehling et al.
Neurology, 76(8 Suppl 3), S20-S27 (2011-02-26)
The oral sphingosine 1-phosphate (S1P) receptor (S1PR) modulator fingolimod has been shown to be effective in the treatment of patients with relapsing multiple sclerosis (MS). The drug binds with high affinity to 4 of the 5 G-protein-coupled S1P receptors (S1P(1-5)).
Fingolimod and teriflunomide attenuate neurodegeneration in mouse models of neuronal ceroid lipofuscinosis.
Groh J, et al.
Molecular Therapy, 25(8), 1889-1899 (2017)
The sphingosine-1-phosphate analogue, FTY-720, promotes the proliferation of embryonic neural stem cells, enhances hippocampal neurogenesis and learning and memory abilities in adult mice.
Sun Y, et al.
British Journal of Pharmacology, 173(18), 2793-2807 (2016)
Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment.
Linda Rolf et al.
Neurology, 82(11), 1008-1009 (2014-02-14)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service